Glucotrack reports FY2025 net loss $19.4M; cash $7.4M; plans IDE filing Q2 2026

Glucotrack, Inc.

Net loss for FY2025 was $19.4M, down from $22.6M in 2024; no product revenue.
Cash and equivalents $7.4M at Dec 31, 2025, up from $5.6M; raised $4.0M private placement in Dec 2025.
R&D expenses $9.8M vs $9.5M; G&A $6.3M vs $5.1M year-over-year.
Expects to file IDE with FDA in Q2 2026 to start US clinical feasibility study of implantable CBGM in H2 2026.
Believes existing cash sufficient only through Spring 2026 to fund IDE submission and trial initiation.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Glucotrack, Inc. reported full year ended December 31, 2025 results: net income Net loss for the full year 2025 was $19.4 million.

Period: full year ended December 31, 2025
Net income: Net loss for the full year 2025 was $19.4 million
Result: reported results

Exact text from the filing

Glucotrack, Inc. (the “Company”) issued a press release announcing its financial and operating results for the year ended December 31, 2025.

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

Glucotrack, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-013654

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.